Uro (Mar 2023)

Prostate Cancer: Advances in Genetic Testing and Clinical Implications

  • Ahmad S. Abdelrazek,
  • Khaled Ghoniem,
  • Mohamed E. Ahmed,
  • Vidhu Joshi,
  • Ahmed M. Mahmoud,
  • Nader Saeed,
  • Nazih Khater,
  • Mohammed S. Elsharkawy,
  • Ahmed Gamal,
  • Eugene Kwon,
  • Ayse Tuba Kendi

DOI
https://doi.org/10.3390/uro3020012
Journal volume & issue
Vol. 3, no. 2
pp. 91 – 103

Abstract

Read online

The demand for genetic testing (GT) for prostate cancer (PCa) is expanding, but there is limited knowledge about the genetic counseling (GC) needs of men. A strong-to-moderate inherited genetic predisposition causes approximately 5–20% of prostate cancer (PCa). In men with prostate cancer, germline testing may benefit the patient by informing treatment options, and if a mutation is noticed, it may also guide screening for other cancers and have family implications for cascade genetic testing (testing of close relatives for the same germline mutation). Relatives with the same germline mutations may be eligible for early cancer detection strategies and preventive measures. Cascade family testing can be favorable for family members, but it is currently unutilized, and strategies to overcome obstacles like knowledge deficiency, family communication, lack of access to genetic services, and testing expenses are needed. In this review, we will look at the genetic factors that have been linked to prostate cancer, as well as the role of genetic counseling and testing in the early detection of advanced prostate cancer.

Keywords